

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
July 5, 2019**

**ORDER GRANTING CONFIDENTIAL TREATMENT UNDER
THE SECURITIES ACT OF 1933 AND
THE SECURITIES EXCHANGE ACT OF 1934**

**Accelaron Pharma Inc.
File Nos. 333-190417 and 001-36065
CF#33985**

Accelaron Pharma Inc. submitted an application under Rules 406 and 24b-2 requesting an extension of a previous grant of confidential treatment for information it excluded from Exhibits to a Form S-1 filed on August 7, 2013, as amended, and as modified by Exhibits refiled with fewer redactions to a Form 10-Q filed on August 4, 2016.

Based on representations by Accelaron Pharma Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibits will not be released to the public for the time periods specified:

<u>Exhibit</u>	<u>to Form</u>	<u>Filed on</u>	<u>Confidential Treatment Granted Through</u>
10.6	S-1	August 7, 2013	July 3, 2022
10.1	10-Q	August 4, 2016	July 3, 2022

For the Commission, by the Division of Corporation Finance, pursuant to Delegated Authority:

Vanessa A. Countryman
Secretary